Mode
Text Size
Log in / Sign up
Phase 2 N=5 Randomized Double-blind Treatment

A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

Acute Myeloid Leukemia

Enrolled (actual)
5
Serious AEs
36.4%
Results posted
Feb 2025
Primary outcome: Primary: Percentage of Safety Events (Part 1, Japan Only) — 5; 0 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Midostaurin (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Novartis Pharmaceuticals
Primary completion
Nov 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Safety Events (Part 1, Japan Only)
5; 0
PRIMARY
Event Free Survival (EFS) (Part 2 - Randomized, Controlled)
7.6; NA
SECONDARY
Overall Survival
NA; NA
SECONDARY
Percentage of Participants With Complete Remission (CR)
70.0; 78.1; 6.7; 0.0; 56.7; 65.6
SECONDARY
Percentage of Participants With Cumulative Incidence of Relapse (CIR)
21; 25
SECONDARY
Pharmakinetics (PK) for Midostaurin: AUClast & AUC0-t
17900; 19200
SECONDARY
Pharmakinetics (PK) for Midostaurin: Cmax
2420
SECONDARY
Metabolite CGP52421: PK Parameters AUClast, AUC0-t
754; 876
SECONDARY
Metabolite CGP52421: PK Parameter Cmax
98.6
SECONDARY
Metabolite CGP62221: PK Parameters: AUClast, AUC0-t
1430; 1730
SECONDARY
Metabolite CGP62221: PK Parameter: Cmax
196
SECONDARY
Change From Baseline in Quality of Life (QoL) Per European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30
27.8; 0.0; 20.8; 37.1; 28.3; 27.8
SECONDARY
Quality of Life (QoL) Per Patient Global Impression of Change (PGIC)
1; 0; 2; 1; 3; 0

Summary

This study evaluated the efficacy and safety of midostaurin in combination with daunorubicin/cytarabine induction, high dose cytarabine consolidation and midostaurin single agent continuation therapy in newly diagnosed patients with FLT3-mutated acute myeloid leukemia (AML).

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of AML (≥ 20% blasts in the bone marrow based on WHO 2016 classification). Patients with APL (acute promyelocytic leukemia) with PML-RARA are not eligible
  • Documented presence of an ITD and/or TKD activating mutation in the FLT3 gene, as determined by analysis in a Novartis designated laboratory An exception will be patients who are enrolled into the part 1 in Japan, who may be treated with midostaurin irrespective of AML FLT3 genotype.
  • Patients must meet the following laboratory value criteria that indicate adequate organ function at the screening visit:
  • Estimated creatinine clearance ≥ 30 ml/min
  • Total bilirubin ≤ 1.5 x ULN, except in the setting of isolated Gilbert syndrome
  • Aspartate transaminase (AST) ≤ 3.0 x ULN
  • Alanine transaminase (ALT) ≤ 3.0 x ULN
  • Suitability for intensive chemotherapy in the judgment of the investigator

Exclusion Criteria

  • Neurologic symptoms suggestive of CNS leukemia unless CNS leukemia has been excluded by a lumbar puncture. Patients with CSF fluid positive for AML blasts are not eligible
  • Developed therapy-related AML after prior radiotherapy (RT) or chemotherapy for another cancer or disorder
  • Known hypersensitivity to midostaurin, cytarabine or daunorubicin or to any of the excipients of midostaurin/placebo, cytarabine or daunorubicin
  • Abnormal chest X-ray unless the abnormality represents a non-active, or non-clinically significant finding, such as scarring (subjects with controlled non active lung infection are eligible)
  • Known impairment of gastrointestinal (GI) function or GI disease that might alter significantly the absorption of midostaurin
  • Cardiac or cardiac repolarization abnormality
  • Pregnant or nursing (lactating) women
  • Women of child-bearing potential, unless they are using highly effective methods of contraception during dosing and for 4 months after stopping medication
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03280030). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search